SecBot SecBot
PRESS-RELEASE ·Filed Mar 25, 2026

DNLI

Denali Therapeutics Inc.
BULLISH
Impact 9/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

AVLAYAH represents Denali’s first commercial product and platform validation. Traders should monitor launch execution, pricing, patient uptake, and PRV monetization plans. Confirmatory trial data from COMPASS will be critical for full approval and long-term commercial viability.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.47
T+0 close · Mar 25, 2026 · via day close
Latest settled
+7.03%
T+60 · $24.05
Vs SPY
−6.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 25 $22.47entry
  2. T+1 · 8mo ago −12.17%α −10.40% · $19.74
  3. T+5 · 8mo ago −12.42%α −12.17% · $19.68
  4. T+20 · 7mo ago −13.44%α −21.30% · $19.45
  5. T+60 · 5mo ago +7.03%α −6.42% · $24.05
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Denali Therapeutics announced FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm), the first biologic therapy designed to cross the blood-brain barrier for the treatment of neurologic manifestations of Hunter syndrome (MPS II). The approval is based on biomarker reduction in cerebrospinal fluid heparan sulfate, with a confirmatory Phase 2/3 trial ongoing. Denali also received a Rare Pediatric Disease Priority Review Voucher (PRV) as part of the approval.

Key Facts

  • FDA granted accelerated approval to AVLAYAH™ for neurologic manifestations of Hunter syndrome (MPS II), a rare lysosomal storage disease.
  • AVLAYAH is the first FDA-approved therapy engineered to cross the blood-brain barrier via Denali’s TransportVehicle™ platform targeting the transferrin receptor.
  • Approval based on 91% reduction in cerebrospinal fluid heparan sulfate (CSF HS) by week 24 in a Phase 1/2 trial, with 93% of patients reaching normal CSF HS levels.
  • Denali received a Rare Pediatric Disease Priority Review Voucher (PRV), which can be sold or used to accelerate review of a future drug application.
  • AVLAYAH is indicated for pediatric patients weighing at least 5 kg with early-stage disease; confirmatory Phase 2/3 COMPASS trial is ongoing.

Financial Impact

Potential blockbuster revenue given first-in-class status and unmet need; PRV could be worth $100M+ if sold.

revenuevaluationdilution

Risk Factors

  • Accelerated approval requires verification of clinical benefit in ongoing COMPASS trial; failure could lead to withdrawal.
  • Safety concerns including anaphylaxis, infusion reactions, anemia, and membranous nephropathy may limit adoption.
  • Competition from gene therapies or next-generation ERTs in development for MPS II.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262412

Track record

17 reports on DNLI

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 25, 2026